Dermatofibroma classification

Dermatofibroma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Dermatofibroma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Dermatofibroma classification On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Dermatofibroma classification All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Dermatofibroma classification
CDC on Dermatofibroma classification
Dermatofibroma classification in the news
Blogs on Dermatofibroma classification
Directions to Hospitals Treating Type page name here
Risk calculators and risk factors for Dermatofibroma classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]

Overview

Dermatofibromas are classed as benign skin lesions, meaning that they are completely harmless, though they may be confused with a variety of subcutaneous tumours. Deep penetrating dermatofibromas may be difficult to distinguish, even histologically, from rare malignant fibrohistocytic tumours like dermatofibrosarcoma protuberans.

Classification

Dermatofibromas are classed as benign skin lesions, meaning that they are completely harmless, though they may be confused with a variety of subcutaneous tumours. Deep penetrating dermatofibromas may be difficult to distinguish, even histologically, from rare malignant fibrohistocytic tumours like dermatofibrosarcoma protuberans.

Overview

There is no established system for the classification of [disease name].

Dermatofibroma may be classified according to [classification method] into [number] subtypes/groups: [group1], [group2], [group3], and [group4].

[Disease name] may be classified into [large number > 6] subtypes based on [classification method 1], [classification method 2], and [classification method 3]. [Disease name] may be classified into several subtypes based on [classification method 1], [classification method 2], and [classification method 3].

Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.

If the staging system involves specific and characteristic findings and features: According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].

The staging of [malignancy name] is based on the [staging system].

There is no established system for the staging of [malignancy name].

Classification

Dermatofibroma may be classified according to histopathology into [number] subtypes/groups:

• [Group1]
• [Group2]
• [Group3]
• [Group4]

OR

[Disease name] may be classified into [large number > 6] subtypes based on:

• [Classification method 1]
• [Classification method 2]
• [Classification method 3]

[Disease name] may be classified into several subtypes based on:

• [Classification method 1]
• [Classification method 2]
• [Classification method 3]

OR

Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.

OR

If the staging system involves specific and characteristic findings and features:

According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].

OR

The staging of [malignancy name] is based on the [staging system].

OR

There is no established system for the staging of [malignancy name].

Histopathology varient of dermatofibroma

Tumors

Congenital malformations

Vascular diseases

Inflammatory diseases

Trauma

Retinoblastoma Medulloepithelioma Leukemia Combined retinal hamartoma Astrocytic hamartoma (Bourneville’s tuberous sclerosis)

Persistent fetal vasculature (PFV) Posterior coloboma Retinal fold Myelinated nerve fibers Morning glory syndrome Retinal dysplasia Norrie’s disease Incontinentia pigmenti Cataract

Retinopathy of prematurity (ROP) Coats’ disease Familial exudative vitreoretinopathy (FEVR)

Ocular toxocariasis Congenital toxoplasmosis Congenital cytomegalovirus retinitis Herpes simplex retinitis Other types of fetal iridochoroiditis Endophthalmitis

Intraocular foreign body Vitreous hemorrhage Retinal detachment

The above algorithm is adopted from Clinical Ophthalmic Oncology book